Hanmi Pharmaceutical Co., Ltd. (KR)

https://www.hanmipharm.com

Hanmi Pharmaceutical is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products. The Company is fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea as well as China. The Company invests over 20 percent of its sales in R&D and has over 20 programs in clinical development in three main areas: 1) novel long-acting biologics based on the Company’s LAPSCOVERY™ platform including weekly insulin, weekly to monthly GLP-1, and their combinations (Quantum Project) in diabetes and obesity; 2) novel targeted agents against cancer and autoimmune disorders; and 3) fixed-dose combination programs. *

	Start	2015-07-28 existent
	Industry	pharmaceutical
	Industry 2	lapatinib
	Person	Lee, Gwan Sun (Hanmi Pharmaceutical 201511 CEO)

	Region	Seoul
	Country	Korea, Republic of
	Street	45 Bangi-dong Songpa-gu
	City	138-724 Seoul
	Tel	+82-2-410-9114
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]